1. Louie M, Hogan C, Hurley A, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS. 2003;17:1151–6. [PubMed]
2. Scarsi K, Darin K, Rawizza D, et al. The 10th International AIDS Conference. Vienna: International AIDS Society; 2010. TDF-3TC-NVP is inferior to AZT-3TC-NVP in a large ART program in Nigeria [abstract]
3. Darin K, Scarsi K, Meloni S, Rawizza H, Kanki P. The 10th International AIDS Conference. Vienna: International AIDS Society; 2010. Clinical and virologic outcomes of six first-line regimens in a large ART program in Nigeria.
4. Landman R, Koulla-Shiro S, Sow PS, et al. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society; 2011. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the DAYANA Trial, IMEA032/ANRS12115.
5. Stephan C, Tutschkus M, Khaykin P, et al. 12th European AIDS Conference. Cologne, Germany: European AIDS Clinical Society; 2009. Clinical and lipometabolic outcome of nevirapine- vs efavirenz-initial antiretroviral therapy, both with TDF/FTC-backbone.
6. Rey D, Hoen B, Chavanet P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother. 2009;63:380–8. [PubMed]
7. Towner W, Kerrigan H, LaRiviere M, et al. Efficacy of a once daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study. Int Cong Drug Therapy HIV. 2004
8. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis. 2008;46:1127–9. [PubMed] 9. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339–48. [PubMed] 10. Dejesus E, Mills A, Bhatti L, Conner C, Storfer S. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract. 2011;65:1240–9. [PubMed] 11. Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16:759–69. [PubMed] 12. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363:1499–509. [PMC free article] [PubMed] 13. Vallecillo G, Domingo P, Mallolas J, et al. Evaluation of the safety and effectiveness of nevirapine plus coformulated Tenofovir/Emtricitabine as first-line therapy in routine clinical practice. AIDS Res Hum Retroviruses. 2011 [PubMed] 14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201. [PubMed] 15. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–33. [PubMed]
16. Maggiolo F, Ripamonti D, Migliorino G, et al. XVI International AIDS Conference. Toronto: International AIDS Society; 2006. Comparison of three once-a-day regimens as first-line HAART [Abstract THPE0103]
17. Keiser P, Nassar N, Armas L, Sanchez J, Sandoval J, Moreno S. The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro: International AIDS Society; 2005. An observational cohort comparison of zidovudine-lamivudine-efavirenz vs. tenofovir-lamivudine-efavirenz in anti-retroviral naive patients in a large urban clinic [abstract WePe12.2C20]
18. Torti CD, Quiros-Roldan E, Cologni G, et al. 10th European AIDS Conference. Dublin, Ireland: 2005. Tenofovir+lamivudine+efavirenz versus zidovudine+lamivudine+lopinavir/ritonavir in antiretroviral naive HIV-infected patients: interim results of a prospective randomized study (SISTHER) of the Italian MASTER Cohort; pp. 17–20.
19. DeJesus E, Saple D, Morales-Ramirez J, et al. 48th International conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2008. Elvucitabine phase II 48 Week interim results Show safety and efficacy Profiles similar to lamivudine in treatment naive HIV-1 infected patients with a Unique pharmacokinetic Profile [abstract H-892]
20. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. [PubMed] 21. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806. [PubMed] 22. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–56. [PMC free article] [PubMed] 23. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57. [PubMed] 24. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010;51:855–64. [PubMed]
25. Campbell T, Smeaton L, Kumarasamy N, et al. 18th conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: Foundation for Retrovirology and Human Health; 2011. Efficacy and safety of EFV with either co-formulated 3TC/ZDV or FTC/TDF for initial treatment of HIV-1-infected men and women in diverse multinational settings: ACTG PEARLS Study [abstract 149LB]
26. Miro JM, Manzardo C, Ferrer E, et al. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society; 2011. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients taking antiretroviral regimens based on efavirenz, lopinavir-ritonavir, and atazanavir-ritonavir: 48-week results of a randomized controlled trial (the Advanz-3 trial)
27. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238–46. [PubMed] 28. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25:F7–12. [PubMed]
29. Vernazza P, Wang C, Pozniak A, et al. 6th IAS Conference on HIV Pathogenesis Treatment, Prevention. Rome, Italy: International AIDS Society; 2011. Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015)
30. Bowman V, Rieg G, Jain S, et al. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: International AIDS Society; 2011. 48 Week results of a pilot randomized study of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen of raltegravir (RAL) + lopinavir/ritonavir (LPV/r) versus efavirenz/tenofovir disoproxil fumarate/ emtricitabine (EFV/TDF/FTC) in antiretroviral-naive patients: CCTG 589.
31. Gay CL, Mayo AJ, Mfalila CK, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011;25:941–9. [PMC free article] [PubMed] 32. Landman R, Poupard M, Diallo M, et al. Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 2009;8:379–84. [PubMed]
33. Das S, Arumainayagam J, Kumari B, Chandramani S, Riddell L, Ghanem M. The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients. J Int AIDS Soc. 2008;11(Suppl 1)
34. Malhotra S, Kao A, Liu A, Estes R, Pitrak D. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney: International AIDS Society; 2007. Benefits of HAART in a minority, urban clinic compared to a published randomized, controlled trial.
35. Perez-Valero I, Martin N, Valiente B, et al. Naive patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill. J Int AIDS Soc. 2010;13(Suppl 4):P122.
36. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008;134:147–56. [PMC free article] [PubMed] 37. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–63. [PubMed] 38. van den Berg-Wolf M, Hullsiek KH, Peng G, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008;9:324–36. [PubMed] 39. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22:2117–25. [PMC free article] [PubMed] 40. Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002;3:296–303. [PubMed] 41. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53–61. [PubMed] 42. Cooper CL, van Heeswijk RP. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 2007;8:1–7. [PubMed] 43. Macgregor TR. “Forgiving” a missed daily dose. AIDS Res Hum Retroviruses. 2011;27:345–6. [PMC free article] [PubMed] 44. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antivir Ther. 2001;6:83–8. [PubMed] 45. Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–82. [PMC free article] [PubMed] 46. Wang LH, Begley J, St Claire RL, 3rd, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20:1173–82. [PubMed] 47. Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921–30. [PubMed] 48. Landman R, Descamps D, Peytavin G, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials. 2005;6:291–301. [PubMed] 49. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409–17. [PubMed]